Eli Lilly Said to Play Down Risk of Top Pill
112414
Internal documents show that the company knew of serious side effects of Zyprexa, its best-selling medication for schizophrenia.
496920
Eli Lilly and Co. (LLY.N: Quote, Profile, Research) on Thursday said it expects 2005 earnings to rise as higher sales of its newer drugs offset a decline in its top-selling schizophrenia drug Zyprexa.
609109
FRIDAY, Sept. 14 (HealthDay News) -- The Eli Lilly drug Evista (raloxifene) has been approved by the U.S. Food and Drug Administration to reduce the risk of invasive breast cancer among postmenopausal at high risk for the disease and among postmenopausal women with osteoporosis.
196823
A potent new anti-clotting drug from Eli  Lilly and Co proved as safe and effective as Sanofi-Aventis's  top-seller Plavix in a mid-stage clinical trial, researchers  said on Sunday.  Now Lilly and its partner Sankyo Co. Ltd. aim to demonstrate  clear superiority for their compound, known as prasugrel or  CS-747, in a much larger Phase III study involving up to 13,000  patients that is about to get under way.
615212
Eli Lilly and Co. LLY.N on Thursday  said it expects earnings in 2005 to rise to between $3.05 and  $3.15 per share before special items as growing sales of newer  medicines more than offset disappointing sales of its  top-selling schizophrenia drug.
718380
Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon.
606892
NEW YORK -- Eli Lilly and Co. has downplayed for about 10 years the risks associated with Zyprexa, which treats schizophrenia, The New York Times said on its website yesterday, citing internal documents from the drug maker and e-mail messages of its managers.
105442
Eli Lilly and Co.  on Thursday forecast profit gains next year below its expected 2006 growth and offered few big surprises at a meeting to describe its experimental drugs, sending shares lower.
453137
An experimental drug from Eli Lilly reduced heart attacks in patients with heart disease by 24 percent compared with the current standard treatment.
712690
Eli Lilly &amp; Co. said Thursday it expects 2005 earnings, excluding the impact of expensing stock options, to be in line with analysts&#39; views.
28075
Eli Lilly and Co  plans to submit a U.S. application next week for its experimental blood-clot preventer prasugrel, the most important drug in its pipeline, a company spokesman said on Wednesday.
455038
U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's and Schering-Plough Corp's popular cholesterol drug Vytorin after a study showed it was no better than a generic in preventing the build-up of fatty plaque.
244370
U.S. stocks fell on Friday dragged  down by a string of negative reports from drug makers, with  Pfizer Inc. PFE.N, AstraZeneca Plc. AZN.L and Eli Lilly and  Co. LLY.N delivering bad news about key products.
71924
Drugmaker Eli Lilly and Co.  on Wednesday said its restructuring will result in a fourth-quarter charge of 24 cents to 27 cents per share, above its previous estimate of 19 to 24 cents per share.
266098
NEW YORK, December 9  - Eli Lilly and Co (LLY.NYS) guided to earnings growth in 2005 today, driven by the accelerating sales of its newer drugs.
188910
Eli Lilly and Co. on Friday said it  added a warning to the label of its attention  deficit/hyperactivity disorder medicine, advising patients with  jaundice or a liver injury to stop taking the treatment.
20825
Shares of Indianapolis-based drugmaker  Eli Lilly and Co. LLY.N, maker of antidepressant drug Prozac,  nudged nearly 1 percent lower on Friday.